DOCSLIB.ORG

Cedars-Sinai Chargemaster 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Cedars-Sinai Medical Center AB-1045 Chargemaster Submission Prices Effective July 1, 2021 CPT/ Charge OP/ Default IP/ER Description HCPCS Code Price Price Code 02600001 HB IV INFUS HYDRATION 31-60 MIN 96360 $2,049.01 $2,665.08 02600002 HB IV INFUSION HYDRATION ADDL HR 96361 $502.12 $649.97 02600003 HB IV INFUSION THERAPY 1ST HR 96365 $2,294.89 $2,984.91 02600004 HB IV THERAPY ADDL SEQ UP TO 1 HR 96367 $502.12 $649.97 02600005 HB IV THERAPY-CONCURRENT 96368 $700.35 $907.85 02600007 HB INFUSION SC INITIAL FIRST HR 96369 $942.60 $1,225.38 02600008 HB SC INFUSION ADD'L HOURS 96370 $468.23 $608.70 02600012 HB IV INFUSION THERAPY EA ADDL HR 96366 $502.12 $649.97 02600013 HB IV PUSH INITIAL 96374 $1,253.71 $1,629.84 02600014 HB IV PUSH ADDL SEQ NEW DRUG 96375 $893.88 $1,162.05 02600015 HB IVP ADDL SEQ SAME DRUG 96376 $940.84 $1,223.10 02600017 HB APPL ON-BODY INJECTOR SUBQ INJ 96377 $468.23 02700005 HB CYTOTOXIC SPILL KIT $252.20 02700007 HB 24 HR PH PROBE $3,194.60 02700008 HB FEMSTOP $762.42 02700009 HB PC IPPB KIT $348.08 02700016 HB PEFR-EQUIPMENT $913.64 02700018 HB PC AERO KIT $1,868.84 02700020 HB PC O/P USN EQUIPMENT $1,054.19 02700021 HB PC MICRO-SPIROMETER $11,489.64 02700022 HB PC O/P HHN EQUIPMENT $667.65 02700033 HB STOCKINETTE,2"X25YD/BOX $301.10 02700034 HB DILATOR, RDS $2,968.15 02700035 HB NEEDLE, BIOPSY/ASP/LOC/INJ $428.94 02700036 HB POWER MODULE BACK BATTERY Q0496 $1,971.27 02700042 HB HMGG, TRAVEL CASE Q0508 $758.94 02700044 HB METANEB RT DEVICE KIT $2,315.11 02700045 HB PC METANEB KIT $348.08 02700046 HB HM MODULAR CABLE Q0509 $27,908.70 02710001 HB SUPPORTER, SCROTAL $878.47 02710002 HB SPLINT FOREARM - SMALL $506.19 02710003 HB SPLINT, SUGARTONG $2,785.66 02710005 HB SPICA - HIP (SINGLE OR DOUBLE) $5,502.06 02710006 HB COLLAR, CERVICAL $683.29 02710009 HB CAST, SHORT ARM CAST $1,779.83 02710012 HB PADS R2 EP STUDY $777.89 02710013 HB SPLINT FINGER 2 INCHES $361.24 02710014 HB MUCUS CLEARING DEVICE $363.13 02710018 HB BILE BAG REG $636.70 02710019 HB FECAL INCONTINENCE COLLECTOR $519.25 02710022 HB PC PEP VALVE $411.14 02710023 HB SPLINT WRIST - LARGE $433.48 Ancillary FY22 1 of 231 Cedars-Sinai Medical Center AB-1045 Chargemaster Submission Prices Effective July 1, 2021 CPT/ Charge OP/ Default IP/ER Description HCPCS Code Price Price Code 02710024 HB SPLINT WRIST - MEDIUM $433.48 02710027 HB PENTAMIDINE KIT $515.14 02710029 HB SPLINT, WRIST $1,215.76 02710032 HB SUPPORT LUMBO-SACRAL $1,329.46 02710033 HB KNEE IMMOBILIZER $1,372.86 02710035 HB AEROSOL INHAL, PENTAM ADD'L 10 $1,478.41 02710036 HB SPICA - THUMB OR FINGER $1,661.25 02710037 HB BI-VALVE OR DC CAST $400.08 02710038 HB KIT, OSTOMY 5PK (1 PIECE) $1,692.37 02710039 HB SPLINT, MOLDED $1,712.51 02710041 HB EAR LAVAGE $482.73 02710044 HB 02 CONNECTION TUBING MASK $485.54 02710045 HB HEADSET NAVIGATION DEVICE $501.06 02710047 HB SPLINT FOREARM - MEDIUM $613.49 02710050 HB SPICA CAST - INFANT $181.61 02710053 HB PC HELIOX ADMIN. PER HOUR $228.21 02710054 HB PC NITROGEN ADMIN. PER HOUR $228.21 02710055 HB ILEOSTOMY POUCH $848.98 02710056 HB UNIVALVE CAST OR SPLINT $264.08 02710057 HB PC H.H.N. KIT $435.35 02710058 HB SPLINT FOREARM - LARGE $728.90 02710059 HB SPLINT,THUMB $763.16 02710060 HB PAG-HEART NEB EQUIP $780.86 02710061 HB PASSY MUIR SPEAKING VALVE $803.67 02710063 HB STOMAHESIVE WAFER $821.54 02710064 HB SPLINT, ARM $979.70 02710067 HB PENTAMIDINE EQUIPMENT OP * $1,183.05 02710070 HB SPLINT, KNEE VELCRO $4,898.34 02710073 HB CAST, SHORT LEG WALKING $2,233.99 02710074 HB CAST, CYLINDER THIGH TO ANKLE $2,536.68 02710077 HB CAST, PATELLAR TENDON BEARING $3,161.24 02710078 HB CAST, LONG LEG $3,680.96 02710080 HB KIT, WOUND CLEASING $308.72 02710081 HB SPLINT, SHORT/LONG LEG $2,990.49 02710083 HB PUMP DISCONNECT KIT $137.29 02710085 HB SPLINT WRIST - SMALL $361.24 02710087 HB CAST, SHOE $740.63 02710089 HB CAST SHORT LEG $9,285.31 02710090 HB CAST, LONG ARM $4,478.11 02710091 HB CAST, LONG LEG WALKING $2,233.99 02710101 HB SPLINT, IMMOBILIZER KNEE $1,372.86 02710104 HB SPLINT,IMMOBILIZER SHOULDER $220.06 Ancillary FY22 2 of 231 Cedars-Sinai Medical Center AB-1045 Chargemaster Submission Prices Effective July 1, 2021 CPT/ Charge OP/ Default IP/ER Description HCPCS Code Price Price Code 02720001 HB BASKET GEMINI 3FR $1,923.83 02720003 HB CRYOCATH, FROSTBYTE CLAMP $14,214.18 02720008 HB MEDIA FOR IUI $226.08 02720009 HB WIRE, MICRO EXCHANGE $2,646.13 02720010 HB CATH PERIPHERAL DILITATION C1725 $2,729.50 02720016 HB LASER FIBER, 3 $4,212.23 02720017 HB NEUROPEN WITH NEUROENDOSCOPES $4,406.60 02720018 HB VALVE, DRAINAGE/FARRELL $305.78 02720021 HB CATH DELIVERY SYSTEM $6,746.55 02720023 HB LASER FIBER, 9 $8,693.09 02720025 HB CATH INTRA-AORTC BALLOON $15,893.93 02720034 HB CLIP SURGICAL SPRING CLIP $216.90 02720035 HB KIT, OSTOMY (2 PIECE) $1,150.21 02720036 HB LEVEL I TUBING D-50 $1,169.85 02720037 HB DRAIN 1 $370.43 02720039 HB ENDOSCOPIC VERSATEP $1,002.86 02720040 HB ENDO LLETZ BALL ELCTRODE $318.49 02720044 HB ENDOSCOPE SHEATH DISPOSABLE $584.69 02720045 HB COLOSTOMY BAG $585.72 02720046 HB KYPHON BONE FILLER DEVICE OR $1,213.38 02720047 HB CATHETER, EPISTAXIS BALLOON $597.74 02720048 HB ENDO ELECTRODE CUTTING LOOP $976.36 02720049 HB SHEATH, PERITONEAL/AMPLATZ $606.67 02720050 HB PC NASAL MASKS BIPAP $1,236.22 02720051 HB ENDO IRRIG ENDO-FLO 0037970 $616.13 02720053 HB BIOPSY BRUSH COOK 040310 $619.28 02720054 HB NEEDLE, SCLEROSING $1,265.85 02720055 HB CATH FOLEY W/THERMISTER $529.21 02720056 HB CANNULA, CORONARY PERFUSION DL $621.78 02720058 HB ELECTRODE, ACRIM/MENIS/PEN $622.94 02720059 HB CATHETER, UMBILICAL VES $623.04 02720064 HB CANNULA AVR CABG KIT $641.27 02720068 HB TRACH TUBE #14 $1,301.48 02720072 HB CLAMP, DISPOSABLE $417.20 02720073 HB FILTER, BLOOD TRANSFUSION * $678.92 02720074 HB PACING WIRE, TEMPORARY $828.77 02720075 HB LEADWIRE, EKG $157.17 02720077 HB FRAZIER SUCTION TIPS $333.38 02720080 HB HANDLE, ENDOSCOPIC GIA $1,015.79 02720081 HB TROCAR, ENDOSCOPIC 1 $572.82 02720082 HB CLIP GUN MAGAZINE $333.20 02720084 HB NEEDLE, SPINAL/DISC $723.71 Ancillary FY22 3 of 231 Cedars-Sinai Medical Center AB-1045 Chargemaster Submission Prices Effective July 1, 2021 CPT/ Charge OP/ Default IP/ER Description HCPCS Code Price Price Code 02720086 HB KIT, PACEMAKER 1 $728.70 02720088 HB INTRODUCER, OSTEO ONE STEP $8,207.28 02720089 HB CATHETER, THORACIC MM $745.40 02720090 HB CATHETER PASSER $963.06 02720093 HB PIN, DISTRACTION 1 $563.60 02720096 HB ENDO TIP CAUTERY PEDS RT ANGLE $754.44 02720098 HB LACRIMAL INTUBATION SET $760.76 02720099 HB ROD, OSTOMY $228.63 02720101 HB PEN, HEATING LACTOSORB PLATE $840.17 02720104 HB ENDO BIPOLAR EBF01 $785.02 02720107 HB GRASPER, ENDOSCOPIC 1 $1,164.25 02720108 HB PIN SKULL PINS MAYFIELD- OMI $226.37 02720110 HB PREP DURA $211.66 02720111 HB BLADE, TREPHINE $811.05 02720112 HB LTA KIT $357.08 02720114 HB TUBING, INSUFFLATION $439.25 02720115 HB KYPHON BONE ACCESS NEEDLE 11 G $348.92 02720116 HB ANTENNA,EXTRNL NEUROSTIMALUTOR $1,123.06 02720121 HB SPLINT DENVER SERIES $264.47 02720123 HB ADHESIVE, SKIN 1 $391.28 02720124 HB 23G BIPOLAR TAPERED FINE POINT $493.53 02720125 HB SYRINGE MEDRAD POWER INJECTOR $180.46 02720126 HB ARTHRO, MENISCAL SYSTEM $1,383.12 02720132 HB FILTER MILEX $87.34 02720133 HB SONOHYSTOGRAM CATHETER $257.16 02720135 HB NET, RETRIEVAL ROTH $1,321.32 02720137 HB OSTENE BONE HEMOSTASIS 2.5GRMS $874.45 02720139 HB TUBE, JEJUN FEED/SGL LUMEN $1,403.05 02720140 HB FORCEPS, BIOPSY 1 $537.00 02720144 HB TUBE,TRACH DCT/DFEN W/DISP CAN $1,547.28 02720145 HB KIT, NEUROSTIMULATOR 1 $1,048.05 02720148 HB MEDTRONIC REFILL KIT $1,548.79 02720153 HB TUNNELING ROD, CATH PASSER $1,325.98 02720154 HB TUBE, MIC (FEEDING) $2,318.28 02720159 HB TOOL, DISSECTING 2 $1,540.32 02720161 HB KIT, TRANFIX/BIO-TENODESIS $1,600.03 02720162 HB NEEDLE, ELECT/BEVEL/TROCAR $1,644.04 02720165 HB HEMOSTAT, SOF-GRIP $817.31 02720166 HB BAG DRAINAGE URINARY $269.93 02720168 HB CUTTER, LOCKING LEAD $1,065.94 02720169 HB PERF QUICK PRIME LINE $277.65 02720170 HB ENDO PROBE HANDPIECE $830.59 Ancillary FY22 4 of 231 Cedars-Sinai Medical Center AB-1045 Chargemaster Submission Prices Effective July 1, 2021 CPT/ Charge OP/ Default IP/ER Description HCPCS Code Price Price Code 02720171 HB PC MICRO BRUSH $2,020.50 02720172 HB STRIPPER VEIN DISPOSABLE $841.62 02720174 HB PLEUR-EVAC $2,373.68 02720175 HB SPENCER DEPTH ELECTRODES 8 CON $2,465.79 02720176 HB NEEDLE, OSTYCUT $850.28 02720177 HB T-TUBE, 2 $851.92 02720178 HB ENDO TROCAR 10MM BLNT OMST10BT $861.35 02720183 HB ILIUMINATOR, LIGHTMAT SURGICAL $871.58 02720184 HB PC BROCH OCC CATH C2628 $1,899.64 02720185 HB PERF HEMOCONCENTRATOR PEDS $899.03 02720187 HB TWIST DRILL SURGICAL 1 $905.31 02720189 HB KIT, KYPHOPLASTY INTRO SYSTEM $18,248.13 02720190 HB TRACH PERCUTANEOUS SET $735.97 02720191 HB ENDO SUCTION/IRRIG/PROBE $917.91 02720193 HB CATHETER, MULTI LUMEN $919.68 02720195 HB CANNULA, RETROGRADE CARDIOPLEG $930.89 02720198 HB CANNULA, RETROGRADE 1 $943.04 02720199 HB IV PUMP SET, NITROGLYCERIN $748.31 02720201 HB ARTHRO WAND 1 $1,895.51 02720202 HB BLADE, ACROM/BLASTER/MIONIZER $891.71 02720208 HB IRRIGATION SET, CYSTO $775.50 02720213 HB PERF RESERVOIR CARDIOTOMY $987.03 02720215 HB RESERVOIR, DRAIN 1 $281.65 02720216 HB DRAIN LUMBAR DRAINAGE SET $995.30 02720218 HB PACK, AFFINITY VAVD ACCESSORY $525.82 02720225 HB SHOULDER SUSPENSION KIT 2 $1,023.07 02720228 HB LP DRAINAGE KIT $1,037.33 02720229 HB TUBE, RECTAL $588.79 02720230 HB RADIAL ARTERY KIT $600.40 02720231 HB ENDO POLY LOOP $1,381.78 02720232 HB TUBING, PCA $607.94 02720233 HB TUBE, GASTROSTOMY 1 $620.13 02720235
Recommended publications
  • Oral Presentations September 23Rd - Rooms 1,2 and 3

    Oral Presentations September 23Rd - Rooms 1,2 and 3

    Oral Presentations September 23rd - Rooms 1,2 and 3 Presentation Date Abstract Authors Presenter´s name - Theme Title Code indicated by the author 18498 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of PERFORMANCE OF AN IMMUNOASSAY Eric Franssen; Milly Attema-de abuse METHOD FOR GAMMA-HYDROXYBUTYRIC Jonge ACID (GHB) IN PATIENTS PRESENTED AT THE EMERGENCY DEPARTMENT, A PROSPECTIVE STUDY 18499 Thomas Smits; Femke Gresnigt; Thomas Smits Clinical Toxicology/drugs of DO WE NEED POINT-OF-CARE TESTING OF Milly Attema-de Jonge; Eric abuse GAMMA-HYDROXYBUTYRIC ACID (GHB) AT Fransse THE EMERGENCY DEPARTMENT? September 23 18730 Lilian H.J. Richter; Julia Menges; Lea Wagmann Clinical Toxicology/drugs of NEW PSYCHOACTIVE SUBSTANCES: Lea Wagmann; Simon D. Brandt; abuse METABOLIC FATE, ISOZYME-MAPPING, 13:30 - 14:45 Folker Westphal; Veit Flockerzi; AND PLASMA PROTEIN BINDING OF 5-APB- ROOM 1 Markus R. Meyer NBOME, 2C-B-FLY-NB2ETO5CL, AND 2C-B- FLY-NBOME 18985 Annelies Cannaert; Marie Annelies Cannaert Clinical Toxicology/drugs of HIDE AND SEEK: OVERCOMING THE Deventer; Melissa Fogarty; abuse MASKING EFFECT OF OPIOID Amanda L.A. Mohr; Christophe P. ANTAGONISTS IN ACTIVITY-BASED Stove SCREENING TESTS 18740 Souleiman El Balkhi ; Roland Souleiman El Balkhi Clinical Toxicology/drugs of METABOLIC INTERACTIONS BETWEEN Lawson; Franck Saint-Marcoux abuse OXYCODONE, BENZODIAZEPINES OR DESIGNER BENZODIAZEPINES PLAY AN IMPORTANT ROLE IN OXYCODONE INTOXICATIONS 19050 Brenda de Winter F de Velde; MN Brenda de Winter Anti-infective drugs POPULATION
  • PPE Requirements Hazardous Drug Handling

    PPE Requirements Hazardous Drug Handling

    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
  • Recombinant Factors for Hemostasis

    Recombinant Factors for Hemostasis

    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Chemical & Biomolecular Engineering Theses, Chemical and Biomolecular Engineering, Dissertations, & Student Research Department of Summer 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses Part of the Biochemical and Biomolecular Engineering Commons Calcaterra, Jennifer, "Recombinant Factors for Hemostasis" (2010). Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research. 5. https://digitalcommons.unl.edu/chemengtheses/5 This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Recombinant Factors for Hemostasis by Jennifer Calcaterra A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Interdepartmental Area of Engineering (Chemical & Biomolecular Engineering) Under the Supervision of Professor William H. Velander Lincoln, Nebraska August, 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra, Ph.D. University of Nebraska, 2010 Adviser: William H. Velander Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military personnel and are the primary cause of death for individuals under 44 years of age. Current techniques used to treat hemorrhage are inadequate for severe bleeding. Preliminary research indicates that fibrin sealants (FS) alone or in combination with a dressing may be more effective; however, it has not been economically feasible for widespread use because of prohibitive costs related to procuring the proteins.
  • Management of Status Epilepticus

    Management of Status Epilepticus

    Published online: 2019-11-21 THIEME Review Article 267 Management of Status Epilepticus Ritesh Lamsal1 Navindra R. Bista1 1Department of Anaesthesiology, Tribhuvan University Teaching Address for correspondence Ritesh Lamsal, MD, DM, Department Hospital, Institute of Medicine, Tribhuvan University, Nepal of Anaesthesiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Tribhuvan University,Kathmandu, Nepal (e-mail: [email protected]). J Neuroanaesthesiol Crit Care 2019;6:267–274 Abstract Status epilepticus (SE) is a life-threatening neurologic condition that requires imme- diate assessment and intervention. Over the past few decades, the duration of seizure Keywords required to define status epilepticus has shortened, reflecting the need to start thera- ► convulsive status py without the slightest delay. The focus of this review is on the management of con- epilepticus vulsive and nonconvulsive status epilepticus in critically ill patients. Initial treatment ► neurocritical care of both forms of status epilepticus includes immediate assessment and stabilization, ► nonconvulsive status and administration of rapidly acting benzodiazepine therapy followed by nonbenzodi- epilepticus azepine antiepileptic drug. Refractory and super-refractory status epilepticus (RSE and ► refractory status SRSE) pose a lot of therapeutic problems, necessitating the administration of contin- epilepticus uous infusion of high doses of anesthetic agents, and carry a high risk of debilitating ► status epilepticus morbidity as well as mortality. ► super-refractory sta- tus epilepticus Introduction occur after 30 minutes of seizure activity. However, this working definition did not indicate the need to immediately Status epilepticus (SE) is a medical and neurologic emergency commence treatment and that permanent neuronal injury that requires immediate evaluation and treatment. It is associat- could occur by the time a clinical diagnosis of SE was made.
  • Critical Access COVID-19 Drugs Shortages (156-40)

    Critical Access COVID-19 Drugs Shortages (156-40)

    Resilient Drug Supply Project: Critical Acute Drug List & Critical COVID-19 Drug List Drug Shortages Reported by ASHP & FDA Shortages as of 8/22/2021 UMN RDSP UMN RDSP ASHP FDA Drug Critical Acute Drugs Drug Category List of 156 List of 40 Drug Drug # Generic Name Critical Acute Critical Shortage Shortage Drugs COVID-19 List List Drugs 1 Cisatracurium Paralytic X X Yes 2 Rocuronium Paralytic X X Yes 3 Vecuronium Paralytic X X Yes Yes 4 Succinylcholine Paralytic X X 5 Atracurium Paralytic X 6 Propofol Sedation X X Yes Yes 7 Midazolam Sedation X X Yes Yes 8 Lorazepam Sedation X X Yes Yes 9 Dexmedetomidine Sedation/Anesthesia X X Yes Yes 10 Phenobarbital Sedation X 11 Ketamine Sedation/Anesthesia X X Yes Yes 12 Diazepam Sedation X 13 Lidocaine Local Anesthetic X Yes Yes 14 Bupivacaine Local Anesthetic X Yes Yes 15 Fentanyl Pain X X Yes Yes 16 Hydromorphone Pain X X Yes Yes 17 Morphine Pain X X Yes Yes 18 Oxycodone Pain X X 19 Acetaminophen Pain & Fever X 20 Ketorolac Pain X Yes Yes 21 Anakinra Pain X 22 Oxygen Medical Gas X X 23 Nitric Oxide Medical Gas X 24 Sevoflurane Medical Gas X 25 Albuterol Bronchodilator X X Yes 26 Ipratropium (Inhaler) Bronchodilator X 27 Azithromycin Anti-infective X X 28 Piperacillin-Tazobactam Anti-infective X X 29 Cefepime Anti-infective X X Yes 30 Ceftriaxone Anti-infective X 31 Vancomycin Anti-infective X X Yes 32 Doxycycline Anti-infective X 33 Meropenem Anti-infective X X 34 Cefazolin Anti-infective X X Yes Yes 35 Levofloxacin Anti-infective X 36 Linezolid Anti-infective X 37 Ampicillin-Sulbactam Anti-infective
  • Absorbable Surgical Gut Suture

    Absorbable Surgical Gut Suture

    Food and Drug Administration, HHS § 878.4840 § 878.4800 Manual surgical instrument in subpart E of part 807 of this chapter, for general use. subject to the limitations in § 878.9. (a) Identification. A manual surgical [53 FR 23872, June 24, 1988, as amended at 61 instrument for general use is a non- FR 1123, Jan. 16, 1996; 66 FR 38803, July 25, powered, hand-held, or hand-manipu- 2001] lated device, either reusable or dispos- able, intended to be used in various § 878.4820 Surgical instrument motors general surgical procedures. The device and accessories/attachments. includes the applicator, clip applier, bi- (a) Identification. Surgical instrument opsy brush, manual dermabrasion motors and accessories are AC-pow- brush, scrub brush, cannula, ligature ered, battery-powered, or air-powered carrier, chisel, clamp, contractor, cu- devices intended for use during surgical rette, cutter, dissector, elevator, skin procedures to provide power to operate graft expander, file, forceps, gouge, in- various accessories or attachments to strument guide, needle guide, hammer, cut hard tissue or bone and soft tissue. hemostat, amputation hook, ligature Accessories or attachments may in- passing and knot-tying instrument, clude a bur, chisel (osteotome), knife, blood lancet, mallet, disposable dermabrasion brush, dermatome, drill or reusable aspiration and injection bit, hammerhead, pin driver, and saw needle, disposable or reusable suturing needle, osteotome, pliers, rasp, re- blade. tainer, retractor, saw, scalpel blade, (b) Classification. Class I (general con- scalpel handle, one-piece scalpel, snare, trols). The device is exempt from the spatula, stapler, disposable or reusable premarket notification procedures in stripper, stylet, suturing apparatus for subpart E of part 807 of this chapter the stomach and intestine, measuring subject to § 878.9.
  • Congenital Heart Disease

    Congenital Heart Disease

    GUEST EDITORIAL Congenital heart disease Pediatric Anesthesia is the only anesthesia journal ded- who developed hypoglycemia were infants. (9). Steven icated exclusively to perioperative issues in children and Nicolson take the opposite approach of ‘first do undergoing procedures under anesthesia and sedation. no harm’ (10). If we do not want ‘tight glycemic con- It is a privilege to be the guest editor of this special trol’ because of concern about hypoglycemic brain issue dedicated to the care of children with heart dis- injury, when should we start treating blood sugars? ease. The target audience is anesthetists who care for There are no clear answers based on neurological out- children with heart disease both during cardiac and comes in children. non-cardiac procedures. The latter takes on increasing Williams and Cohen (11) discuss the care of low importance as children with heart disease undergoing birth weight (LBW) infants and their outcomes. Pre- non-cardiac procedures appear to be at a higher risk maturity and LBW are independent risk factors for for cardiac arrest under anesthesia than those without adverse outcomes after cardiac surgery. Do the anes- heart disease (1). We hope the articles in this special thetics we use add to this insult? If prolonged exposure issue will provide guidelines for management and to volatile anesthetics is bad for the developing neona- spark discussions leading to the production of new tal brain, would avoiding them make for improved guidelines. outcomes? Wise-Faberowski and Loepke (12) review Over a decade ago Austin et al. (2) demonstrated the current research in search of a clear answer and the benefits of neurological monitoring during heart conclude that there isn’t one.
  • PERSONAL INFORMATION Francesco Rodeghiero WORK

    PERSONAL INFORMATION Francesco Rodeghiero WORK

    Curriculum Vitae PERSONAL INFORMATION Francesco Rodeghiero WORK EXPERIENCE February 2004- Present Scientific Director Fondazione Progetto Ematologia (Italy) August 2001-October 2015 Director of the Department of Cell Therapy and Hematology Azienda ULSS N.6 (Italy) <p>The Department includes a Unit for Bone Marrow Transplantation, a specialized Center for the diagnosis and treatment of Hemophilia and Thrombosis, and a Research Laboratory</p> 1989- 2016 Professor at the Postgraduate School of Hematology on a contract-basis University of Verona (Italy) February 1993-October 2015 Director of the Hematology Department Azienda ULSS N.6 (Italy) December 1985-October 2015 Director of the Hemostasis and Trombosis Center Azienda ULSS N.6 (Italy) September 2006-November 2016 Member; Chairman from June 2016 to November 2016 Ethics Committee on drugs research and investigational protocol studies of the Vicenza District (Italy) EDUCATION AND TRAINING July 1975- Degree in Medicine University School of Medicine (Italy) December 1984- Postgraduate specialization in Laboratory Medicine University of Padova (Italy) June 1981- Postgraduate specialization in Oncology University of Ferrara (Italy) July 1978- Postgraduate specialization in Hematology University of Ferrara (Italy) ADDITIONAL INFORMATION 15/12/2020 European Medicine Agency Page 1/46 Expertise He has been conducting clinical research in the fields of hematology and hemostasis since the early 1970s. His main interests include thrombocytopenia, hemophilia, von Willebrand disease, thrombophilia, acute promyelocytic leukemia, myeloma, policytemia vera, and the epidemiological aspects of haematological diseases. In the last decades he mainly devoted to clinical research in the field of ITP. Publications 1.T. Barbui, F. Rodeghiero, E. Dini The aspirin tolerance test in von Willebrands disease.
  • Oral and Maxillofacial Surgery

    Oral and Maxillofacial Surgery

    ORAL AND MAXILLOFACIAL SURGERY 3rd EDITION 2/2012 US Chapter Pages 1 BASIC SETS OMFS-SET 1-36 TELESCOPES AND INSTRUMENTS FOR FRAKT 37-54 2 ENDOSCOPIC FRACTURE TREATMENT TELESCOPES AND INSTRUMENTS FOR TMJ 55-60 3 ARTHROSCOPY OF TEMPOROMANDIBULAR JOINT TELESCOPES AND INSTRUMENTS FOR DENT 61-80 4 MAXILLARY ENDOSCOPY TELESCOPES AND INSTRUMENTS DENT-K 81-120 5 FOR DENTAL SURGERY TELESCOPES AND INSTRUMENTS SIAL 121-134 6 FOR SIALENDOSCOPY 7 FLEXIBLE ENDOSCOPES FL-E 135-142 8 HOSPITAL SUPPLIES HS 143-240 9 INSTRUMENTS FOR RHINOLOGY AND RHINOPLASTY N 241-298 10 BIPOLAR AND UNIPOLAR COAGULATION COA 299-312 11 HEADMIRRORS – HEADLIGHTS OMFS-J 313-324 12 AUTOFLUORESCENCE AF-INTRO, AF 325-342 13 HOLDING SYSTEMS HT 343-356 VISUALIZATION SYSTEMS OMFS-MICRO, OMFS-VITOM 357-378 14 FOR MICROSURGERY OMFS-UNITS-INTRO, UNITS AND ACCESSORIES U 1-54 15 OMFS-UNITS COMPONENTS OMFS-SP SP 1-58 16 SPARE PARTS KARL STORZ OR1 NEO™, TELEPRESENCE 17 HYGIENE, ENDOPROTECT1 ORAL AND MAXILLOFACIAL SURGERY 3rd EDITION 2/2012 US Important information for U.S. customers Note: Certain devices and references made herein to specific indications of use may have not received clearance or ap- proval by the United States Food and Drug Administration. Practitioners in the United States should first consult with their local KARL STORZ representative in order to ascertain product availability and specific labeling claims. Federal (USA) law restricts certain devices referenced herein to sale, distribution, and use by, or on the order of a physician, dentist, veterinarian, or other practitioner licensed by the law of the State in which she/he practices to use or order the use of the device.
  • WHO Model List of Essential Medicines

    WHO Model List of Essential Medicines

    WHO Model List of Essential Medicines 15th list, March 2007 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html 15th edition Essential Medicines WHO Model List (revised March 2007) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost‐effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost‐effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost‐effectiveness in a variety of settings. The square box symbol () is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines.
  • Adverse Health Effects of Heavy Metals in Children

    Adverse Health Effects of Heavy Metals in Children

    TRAINING FOR HEALTH CARE PROVIDERS [Date …Place …Event …Sponsor …Organizer] ADVERSE HEALTH EFFECTS OF HEAVY METALS IN CHILDREN Children's Health and the Environment WHO Training Package for the Health Sector World Health Organization www.who.int/ceh October 2011 1 <<NOTE TO USER: Please add details of the date, time, place and sponsorship of the meeting for which you are using this presentation in the space indicated.>> <<NOTE TO USER: This is a large set of slides from which the presenter should select the most relevant ones to use in a specific presentation. These slides cover many facets of the problem. Present only those slides that apply most directly to the local situation in the region. Please replace the examples, data, pictures and case studies with ones that are relevant to your situation.>> <<NOTE TO USER: This slide set discusses routes of exposure, adverse health effects and case studies from environmental exposure to heavy metals, other than lead and mercury, please go to the modules on lead and mercury for more information on those. Please refer to other modules (e.g. water, neurodevelopment, biomonitoring, environmental and developmental origins of disease) for complementary information>> Children and heavy metals LEARNING OBJECTIVES To define the spectrum of heavy metals (others than lead and mercury) with adverse effects on human health To describe the epidemiology of adverse effects of heavy metals (Arsenic, Cadmium, Copper and Thallium) in children To describe sources and routes of exposure of children to those heavy metals To understand the mechanism and illustrate the clinical effects of heavy metals’ toxicity To discuss the strategy of prevention of heavy metals’ adverse effects 2 The scope of this module is to provide an overview of the public health impact, adverse health effects, epidemiology, mechanism of action and prevention of heavy metals (other than lead and mercury) toxicity in children.
  • November Packet

    November Packet

    L Buckman Dire cl Diversion Date: October 22,2018 To: Buckman Direct Diversion Board From: Michael Dozier, BDD Operations Superintendent .AAD Subject: Update on BDD Operations for the Month of October 2018 ITEM: 1. This memorandum is to update the Buckman Direct Diversion Board (BDDB) on BDD operations during the month of October 2018. The BDD diversions and deliveries have averaged, in Million Gallons Per Day (MOD) as follows: a. Raw water diversions: 5.66 MOD b. Drinking water deliveries through Booster Station 4N5A: 5.08 MOD c. Raw water delivery to Las Campanas at BS2A: 0.53 MOD d. Onsite treated and non-treated water storage: 0.05 MOD Average 2. The BDD is providing approximately 81% percent of the water supply to the City and County for the month. 3. The BDD year-to-date diversions are depicted below: Year-To-Date Comparison 350.00 , I ®.' Buckman Direct Diversion • 341 Caja del Rio Rd. • Santa Fe, NM 87506 1 4. Background Diversion tables: Buckman Direct Diversion Monthly SJC and Native Diversions Oct-18 In Acre-Feet Total SD-03418 SP-4842 SP-2847-E SP-2847-N-A All Partners SJC+ RGNative Month RG Native SJCCall SJCCall Conveyance Native LAS SJCCall COUNTY CITY LASCAMPANAS Losses Rights CAMPANAS Total JAN 380.137 77.791 0.000 302.346 302.346 0.000 3.023 FEB 336.287 66.413 0.000 269.874 169.874 0.000 2.699 MAR 362.730 266.898 0.000 95.832 95.832 0.000 0.958 APR 661.333 568.669 0.000 92.664 92.664 0.000 0.927 MAY 933.072 340.260 0.000 592.812 481.647 111.165 5.928 JUN 873.384 44.160 0.000 829.224 693.960 135.264 8.292 JUL 807.939